Androgen deprivation therapy associated with increased risk for fatal heart attack
the ONA take:
Androgen deprivation therapy (ADT) and radiation therapy (RT) prolong survival in men with unfavorable-risk prostate cancer; however, evidence suggests that ADT is associated with nonfatal cardiovascular events.
Specifically, long-term follow-up of a randomized clinical trial that compared ADT and RT with RT alone showed that men with significant comorbidity, most commonly prior heart attack, who received ADT died earlier. These findings are published in a research letter in the Journal of the American Medical Association.
In this study, overall survival and death due to prostate cancer, fatal heart attack, and all other causes were analyzed. The study included 206 men with unfavorable-risk prostate cancer who were randomized to receive RT alone or RT and 6 months of ADT. The men were also categorized into subgroups based on prior comorbidity, including prior heart attack.
The findings demonstrate that prior heart attack is associated with an increased risk of fatal heart in men who receive ADT for unfavorable-risk prostate cancer.
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|